Front CoverBuy Now!

About the Author:

Rabbi David Shabtai, MD is a fellow of the Wexner Kollel Elyon at the Rabbi Isaac Elchanan Theological Seminary (RIETS). R. Dr. Shabtai received his medical doctorate from NYU School of Medicine and rabbinic ordination from RIETS.

He currently teaches Jewish Medical Ethics at Yeshiva University (Modern Jewish Problems: Halakhic Challenges in Medicine) and RIETS (Medical Halakhah Habburah) and lectures on various topics in Jewish law. He is particularly interested in the interface between science, medicine, and Jewish law.

Feel free to contact R. Dr. Shabtai, to ask a question, start a discussion, or have him come to speak at your synagogue, school, or event via email.


David Shabtai, “Revisiting the USPTF Breast Cancer Screening Guidelines: Ethics and Patient Responsibilities, Clinical Correlations (Faculty Peer Reviewed Blog of NYU Department of Internal Medicine).

Yaakov Jaffe and David Shabtai, “Morgue Construction and Tum’at Kohanim,” Journal of Halacha and Contemporary Society 58 (2009): 60.

Rabbi Yaakov Jaffe and David Shabtai, “Kohanim in Hospitals – Does Tum’ah Enter the Elevator Shafts” (Hebrew), Assia 22 [85-86] (2009): 122.

Yaakov Jaffe and David Shabtai, “It is upon him to bring the proof”: A Note on Historiography, Printing, and the Power of Hearsay in a Position of Rabad,” Hakirah 7 (2009): 165-76.

David Shabtai, “End of Life Therapies,” Journal of Halacha and Contemporary Society 56 (2008): 22

David Shabtai and Raymond Sultan, MD, “Metzitzah b’Peh – Paradigm for Halachic Risk Taking,” Jewish Medical Ethics 6 (2007): 26-48.

David Shabtai and Raymond Sultan, “Medical Risk Taking in Halacha: A Case Study – Metzitzah b’peh,” Journal of Halacha and Contemporary Society, 51 (2006): 12-43.

David Shabtai, “Copepods in NYC Water: A Scientific and Halachic Background,” Journal of Halacha and Contemporary Society 49 (2005): 34-80.

Loike JD, Shabtai DY, et al. “Statin inhibition of Fc receptor-mediated phagocytosis by macrophages is modulated by cell activation and cholesterol.” Arteriosclerosis, Thrombosis, and Vascular Biology 24:11 (2004): 2051-2056.

Lecanda J, Shabtai D, et al. “TGF-beta prevents proteasomal degradation of p27(Kip1) by downregulation of Cks1 and Skp2 for cellular growth inhibition. Molecular Biology of the Cell 15 [Supplement] (2004): 128A.

(c) David Shabtai, 2012 Amazon, and the Amazon logo are trademarks of, Inc. or its affiliates.
Website design by NoVa Web Design